DSPG is used in FDA approved drugs. It is an anionic phospholipid derivative. DSPG has been used to form an ionic complex with amphotericin B and encapsulate it into small unilamellar liposomes with significantly reduced toxicity (AmBisome). DSPG-Na is a lipid reagent, which is useful in drug formulation, DNA & RNA delivery.
(Rac)-1,2-Distearoyl-sn-Glycero-3-Phosphatidylglycerol (sodium) is an anionic phospholipid, can be used for drug delivery and the synthesis of liposomes[1].
Three liposome formulations were investigated: HSPC:Chol (L-EPI; 5:4 molar ratio), HSPC:Chol:DSPG (D-EPI; 5:4:1 molar ratio), and HSPC:Chol:DSPG:DSPE-mPEG(2000) (S-EPI; 5:4:1:0.3 molar ratio). Small unilamellar liposomes were prepared by the modified thin-film hydration method with extrusion through polycarbonate filters, and EPI was remote loaded into liposomes by the transmembrane ammonium sulfate gradient method._x000D_
_x000D_
Reference: J Liposome Res. 2012 Mar;22(1):80-8. https://pubmed.ncbi.nlm.nih.gov/22022836/
Vaccination of atherosclerotic mice on a western-type diet with DSPG-liposomes encapsulating an LDL-derived peptide antigen significantly reduced plaque formation by 50% and stabilized the plaques, and reduced serum cholesterol concentrations. These results indicate that DSPG-liposomes have potential as a delivery system in vaccination against atherosclerosis._x000D_
_x000D_
Reference: J Control Release. 2018 Dec 10;291:135-146. https://pubmed.ncbi.nlm.nih.gov/30365993/
[1] Naomi Benne, et al. Anionic 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) liposomes induce antigen-specific regulatory T cells and prevent atherosclerosis in mice. J Control Release. 2018 Dec 10;291:135-146. DOI:
10.1016/j.jconrel.2018.10.028
